AstraZeneca’s tozorakimab meets primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD: Cambridge, UK Saturday, March 28, 2026, 11:00 Hrs [IST] Posit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results